Consolidation of training-induced changes in unipedal stance: Path Length, X Sway Amplitude and Velocity. by Cristina Dolciotti (16317330)

Subjects:

Time course of 95% Area, X and Y Amplitude Sway during postural training. by Cristina Dolciotti (16317330)

Subjects:

Correlations between unipedal and bipedal stance parameters recorded at the beginning of the training and of the control session. by Cristina Dolciotti (16317330)

Subjects:

Flow diagram. by Cristina Dolciotti (16317330)

Subjects:

Larger example of stimuli with cue relevant for Task 3. by Marcel F. Hinss (14675457)

Early IL-33 administration expands trTregs and improves disease outcome in infected mice. by Santiago Boccardo (5927954)

Subjects:

Degeneration Saline group presented with significant decreased final weight in relation to other groups. by Flavia Gomes Velasque Gama (21175112)

Ranking of factors in order of importance as reported by survey respondents regarding the difficulty in accessing the lower uterine segment (A), complicated fetal extraction in ces... by María Jesús Cancelo Hidalgo (12154030)

Subjects:

Schematic diagram of the molecular mechanism by which TRIM37 improves MS by stabilizing PEX5 through monoubiquitination. by Lai Jiang (2401513)

Subjects:

Parvalbumin-positive interneurons (PV-INs) in perilesional tissue respond to optogenetic stimulation and are involved in voluntary movement, but show a decreased firing rate. by Livia Vignozzi (22430567)

“…<b>E</b>, Quantification of the average firing rate of the recorded PV-INs in response to optogenetic stimulation. A significant decrease in firing activity is evident in stroke animals (Two-tailed <i>T</i> Test *** <i><i>P</i></i> < 0.001). …”

Weekly aerobic exercise volume over time for the DHA and placebo groups combined (n  by Claire M. Douglas (21238238)

Subjects:

Weekly resistance training frequency over time for the DHA and placebo groups combined (n  by Claire M. Douglas (21238238)

Subjects:

Quality of life scores at baseline (week 0) and end of chemotherapy (week 18) in the DHA and placebo groups. by Claire M. Douglas (21238238)

Subjects:

Participant demographic and clinical characteristics. by Claire M. Douglas (21238238)

Subjects:

Quality of life scores at baseline (week 0) and the end of chemotherapy (week 18) in participants that met (≥ 150 minutes/week) or did not meet (< 150 minutes/week) WHO’s aerobic e... by Claire M. Douglas (21238238)

Subjects:

Flow of participants through the DHA WIN RCT. Abbreviations: Docosahexaenoic acid (DHA), Docosahexaenoic acid for Women with Breast Cancer in the Neoadjuvant Setting (DHA WIN), ran... by Claire M. Douglas (21238238)

Subjects:

Quality of life scores at baseline (week 0) and the end of chemotherapy (week 18) in participants that met (≥ 2 times/week) or did not meet (< 2 times/week) WHO’s resistance traini... by Claire M. Douglas (21238238)

Subjects:

Integration of Metabolomics, Transcriptomics, and 16s rRNA Sequencing Reveals the Mechanism of Morus alba <i>L.</i> (Sangzhi) Alkaloids (SZ-A) in Improving Cholesterol Metabolism i... by Caina Li (4126462)

Subjects:

Change in Watt’s Connectedness Scale, Subscales by Treatment Group. by Benjamin R. Lewis (22279166)

Subjects:

Primary and secondary efficacy end points (intention-to-treat population). by Benjamin R. Lewis (22279166)

Subjects: